Proteomic characterization of differentially expressed proteins in breast cancer: Expression of hnRNP H1, RKIP and GRP78 is strongly associated with HER-2/neu status

Proteomics - Clinical Applications

Volumn 2, Issue 1, 2008, Pages 99-107

  Zhang, Daohai ^a,b   Tai, Lee Kian ^b   Wong, Lee Lee ^b   Putti, Thomas C ^b   Sethi, Sunil K ^a,b   Teh, Ming ^b   Koay, Evelyn S C ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Breast cancer; HER 2; Neu oncogene; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE REGULATED PROTEIN 78; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H1; NEU DIFFERENTIATION FACTOR; NEU DIFFERENTIATION FACTOR ALPHA1; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEOME; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SEQUENCE ANALYSIS; SEQUENCE DATABASE; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UPREGULATION;

EID: 38949187296     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780099     Document Type: Article

References (34)

1. Hermanto, U., Zong, C. S., Wang, L-H., ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene 2001, 20, 7551-7562.
2. Tan, M., Grijalva, R., Yu, D., Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Res. 1999, 59, 1620-1625.
3. Menard, S., Tagliabue, E., Campoglio, M., Pupa, S. M., Role of HER2 gone overexpression in breast carcinoma. J. Cell. Physiol. 2000, 182, 150-162.
4. Nahta, R., Esteva, F. J., HER-2-targeted therapy. Lessons learned and future directions. Clin. Cancer Res. 2003, 9, 5078-5084.
5. MacKay, A., Jones, C., Dexter, T., Silva, R. L et al., cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 2003, 22, 2680-2688.
6. Wilson, K. S., Roberts, H., Leek, R., Harris, A. L., Geradts, J., Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am. J. Pathol. 2002, 161, 1171-1185.
7. Wolf-Yadlin, A., Kumar, N., Zhang, Y., Hautaniemi, S. et al., Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol. Syst Biol. 2006, 2, 54.
8. Bose, R., Molina, H., Patterson, A. S., Bitok, J. K. et al., Phosphoproteomic analysis of HER-2/neu signaling and inhibition. Proc. Natl. Acad. Sci. USA 2006, 103, 9773-9778.
9. Friedman, D. B., Wang, S. E., Whitwell, C. W., Caprioli, R. M., Arteaga, C. L, Multivariable difference gel electrophoresis and mass spectrometry: A case study on transforming growth factor-beta and ERBB2 signaling. Mol. Cell. Proteomics 2007, 6, 150-169.
10. Gharbi, S., Gaffney, P., Yang, A., Zvelebil, M. J. et al., Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol. Cell. Proteomics 2002, 1, 91-98.
11. Kumar-Sinha, C., Ignatoski, K. W., Lippman, M. E., Ethier, S. P., Chinnaiyan, A. M., Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res. 2003, 63, 132-139.
12. Zhang, D., Tai, L. K., Wong, L L., Sethi, S. K., Koay, E. S. C., Proteomics of breast cancer: Enhanced expression of cytokeratin 19 in human epidermal growth factor receptor type 2 positive breast tumors. Proteomics 2005, 5, 1797-1805.
13. Zhang, D., Tai, L. K., Wong, L L, Chiu, L-L at al., Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol. Cell. Proteomics 2005, 4, 1686-1696.
14. Keller, E. T., Fu, Z., Brennan, M., The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem. Pharmacol. 2004, 68, 1049-1053.
15. Kamma, H., Portman, D. S., Droyfuss, G., Cell type-specific expression of hnRNP proteins. Exp. Cell Res. 1995, 221, 187-196.
16. Lee, A. S., The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem. Sci. 2001, 26, 504-510.
17. Nagashima, T., Shimodaira, H., Ide, K., Nakakuki, T. et al., Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation. J. Biol. Chem. 2007, 282, 4045-4056.
18. Yeung, K., Seitz, T., Li, S., Janosch, P. et al., Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999, 401, 173-177.
19. Yeung, K., Janosch, P., McFerran, B., Rose, D. W. et al., Mechanism of suppression of the Raf(MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol. Cell. Biol. 2000, 20, 3079-3085.
20. Fu, Z., Smith, P. C., Zhang, L., Rubin, M. A. et al., Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Natl. Cancer Inst. 2003, 95, 878-889.
21. Hagan, S., Al-Mulla, F., Mallon, E., Olen, K. et al., Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin. Cancer Res. 2005, 11, 7392-7397.
22. Corbit, K. C., Trakul, N., Eves, E. M., Diaz, B. et al., Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J. Biol. Chem. 2003, 278, 13061-13068.
23. Minoo, P., Zlobec, I., Baker, K., Tornillo, L. et al., Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am. J. Clin. Pathol. 2007, 127, 820-827.
24. Buratti, E., Baralle, M., De Conti, L., Baralle, D. et al., hnRNP H binding at the 5′ splice site correlates with the pathological effect of two intronic mutations in the NF-1 and TSH beta genes. Nucleic Acids Res. 2004, 32, 4224-4236.
25. Garneau, D., Revil, T., Fisatte, J. F., Chabot B., Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. J. Biol. Chem. 2005, 280, 22641-22650.
26. Honore, B., Vorum, H., Baandrup, U., hnRNPs H, H' and F behave differently with respect to posttranslational cleavage and subcellular localization. FEBS Lett. 1999, 456, 274-280.
27. Honore, B., Baandrup, U., Vorum, H., Heterogeneous nuclear ribonucleoproteins F and H/H' show differential expression in normal and selected cancer tissues. Exp. Cell Res. 2004, 294, 199-209.
28. Riva, S., Morandi, C., Tsoulfas, P., Pandolfo, M. et al., Mammalian single-stranded DNA binding protein UP 1 is derived from the hnRNP core protein A1. EMBO J. 1986, 5, 2267-2273.
29. Lee, A. S., The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 2005, 35, 373-381.
30. Reddy, R. K., Mao, C., Baumeister, P., Austin, R. C. et al., Endoplasmic reticulum chaperone protein GRP78 protects calls from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J. Biol. Chem. 2003, 278, 20915-20924.
31. Li, J., Lee, A. S., Stress induction of GRP78/BiP and its role in cancer. Curr. Mol. Med. 2006, 6, 45-54.
32. Lee, E., Nichols, P., Spicer, D., Groshen, S. et al., GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res. 2006, 66, 7849-7853.
33. Gazit, G., Lu, J., Lee, A. S., Do-regulation of GRP stress protein expression in human breast cancer cell lines. Breast Cancer Res. Treat. 1999, 54, 135-146.
34. Dey, A., Kessova, I. G., Cederbaum, A. I., Decreased protein and mRNA expression of ER stress proteins GRP78 and GRP94 in HepG2 cells over-expressing CYP2E1. Arch. Biochem. Biophys. 2006, 447, 155-166.